RIFADIN Drug Patent Profile

« Back to Dashboard

Which patents cover Rifadin, and when can generic versions of Rifadin launch?

Rifadin is a drug marketed by Sanofi Aventis Us and is included in two NDAs.

The generic ingredient in RIFADIN is rifampin. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rifadin

A generic version of RIFADIN was approved as rifampin by EPIC PHARMA LLC on May 28^th, 1997.

Summary for RIFADIN

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	35
Patent Applications:	4,092
Drug Prices:	Drug price information for RIFADIN
What excipients (inactive ingredients) are in RIFADIN?	RIFADIN excipients list
DailyMed Link:	RIFADIN at DailyMed

See drug prices for RIFADIN

Recent Clinical Trials for RIFADIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
TASK Applied Science	Phase 2
GlaxoSmithKline	Phase 2
University of Cape Town	Phase 3

See all RIFADIN clinical trials

US Patents and Regulatory Information for RIFADIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	RIFADIN	rifampin	CAPSULE;ORAL	050420-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sanofi Aventis Us	RIFADIN	rifampin	CAPSULE;ORAL	050420-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sanofi Aventis Us	RIFADIN	rifampin	INJECTABLE;INJECTION	050627-001	May 25, 1989	AP	RX	Yes	Yes

Rifadin Market Dynamics, Patent Status, Generic Competition, and Financial Trajectory

Last updated: September 25, 2026

Rifadin is the branded formulation of rifampin, an established rifamycin antibiotic used primarily in tuberculosis treatment and in selected prophylaxis indications. Its commercial trajectory is defined by mature generic competition, limited brand differentiation, and procurement-driven demand. The original compound and core formulation protections have expired, and no current Orange Book patent or regulatory exclusivity appears to block abbreviated new drug application competition for rifampin capsules. Sanofi does not separately report Rifadin revenue, so brand-level financial performance cannot be isolated from public filings.

What is Rifadin and how is it used?

Rifadin contains rifampin, also known as rifampicin. It is available as oral capsules and as an intravenous formulation in certain markets. Rifampin inhibits bacterial DNA-dependent RNA polymerase and is a core component of multidrug tuberculosis therapy.

The principal demand drivers are:

• Drug-susceptible tuberculosis treatment
• Tuberculosis prevention and latent tuberculosis infection regimens
• Prophylaxis for meningococcal carriage
• Selected prophylaxis uses involving Haemophilus influenzae type b
• Combination treatment programs supplied through public-health agencies

Rifampin is rarely used as monotherapy for active tuberculosis because resistance develops rapidly. Standard tuberculosis treatment combines rifampin with isoniazid, pyrazinamide and ethambutol during the initial phase, followed by continuation therapy.

The World Health Organization lists rifampicin as an essential medicine and includes rifampicin-containing products in tuberculosis treatment guidance (World Health Organization [WHO], 2023).

What is the FDA regulatory status of Rifadin?

Rifadin was approved in the United States as a prescription antibacterial product. FDA labeling identifies rifampin capsules for tuberculosis treatment and certain prophylaxis indications. Rifadin is a small-molecule drug regulated through the NDA pathway, while competing rifampin products are approved through ANDAs.

Regulatory element	Rifadin status
Active ingredient	Rifampin
Drug class	Rifamycin antibacterial
FDA pathway	NDA for the branded product; ANDA pathway for generics
Main dosage forms	Oral capsules; intravenous formulation in relevant markets
Primary disease area	Tuberculosis
Regulatory exclusivity	Expired
Biologic status	Not applicable
Biosimilar pathway	Not applicable

FDA approval does not confer ongoing commercial protection for the brand. Once regulatory exclusivity and patent rights expire, generic manufacturers can rely on abbreviated applications demonstrating pharmaceutical equivalence and bioequivalence.

What patents protect Rifadin?

Rifadin’s original compound and basic product protections are long expired. Rifampin was discovered and commercialized decades ago, well before the modern patent term applied to most current pharmaceutical launches.

Orange Book status

The relevant commercial question is whether Rifadin has an active Orange Book patent or exclusivity entry that delays generic approval. Public FDA Orange Book records do not indicate a current blocking patent or unexpired exclusivity period for the mature rifampin capsule product. The practical result is that generic applicants do not face the type of patent barrier associated with newer branded drugs.

Protection category	Rifadin position
Composition-of-matter patent	Expired
Original formulation patent	Expired
Regulatory exclusivity	Expired
Current Orange Book blocking protection	No material current barrier identified
Generic approval route	ANDA
Patent-related launch risk	Low relative to patented branded drugs

Patent risk can still arise from a particular combination product, manufacturing process, delivery technology or new tuberculosis regimen. Those rights would not restore exclusivity to the original Rifadin capsule product.

When does Rifadin lose exclusivity?

Rifadin has already lost market exclusivity. The key loss occurred through the expiration of the original patent and regulatory protection associated with rifampin. Generic rifampin products can therefore compete on price, supply reliability and regulatory status.

The product’s commercial lifecycle is best characterized as follows:

Period	Commercial position
Original launch period	Innovator rifampin product with protected market position
Post-patent period	Generic competition and declining brand differentiation
Current mature period	Procurement-led demand, low brand pricing power and supply-chain sensitivity

Unlike newer antibiotics, Rifadin has no meaningful remaining exclusivity runway. The relevant forecast issue is not the timing of patent expiry but the durability of demand for rifampin within tuberculosis programs.

How many patents cover Rifadin today?

No meaningful active patent estate appears to cover the core Rifadin capsule product. Any remaining patents that mention rifampin are more likely to concern:

• Combination regimens
• Modified-release systems
• Nanoparticle or particulate formulations
• Manufacturing and crystallization methods
• New therapeutic uses
• Fixed-dose tuberculosis combinations
• Rifampin delivery technologies

These rights would generally have narrower scope than a composition-of-matter patent. They may affect a particular generic product or formulation but do not provide broad exclusivity over rifampin.

Which companies compete with Rifadin?

Rifadin competes primarily with generic rifampin manufacturers rather than with a comparable branded product. In tuberculosis, purchasing decisions are often made by governments, international organizations, hospitals and public-health programs. The active ingredient is frequently supplied through generic or fixed-dose combination products.

Direct generic competition

The competitive field includes manufacturers with approved or quality-assured rifampin products in the United States and international markets. The relevant competitors vary by jurisdiction and procurement tender. Companies active in tuberculosis medicines include major Indian and multinational generic manufacturers, as well as regional suppliers and specialized public-health manufacturers.

The competitive factors are:

1. Regulatory approval and quality certification
2. Ability to maintain uninterrupted supply
3. Manufacturing scale
4. Price in public tenders
5. Product inclusion in national tuberculosis programs
6. Bioequivalence and dissolution performance
7. Packaging and stability in high-temperature markets

Therapeutic alternatives

Rifadin also competes indirectly with other rifamycins:

Product or ingredient	Commercial relevance
Rifapentine	Used in selected tuberculosis treatment and prevention regimens; branded as Priftin in the United States
Rifabutin	Used in specific tuberculosis and mycobacterial settings, including situations involving drug interactions
Rifampin fixed-dose combinations	Major alternative in public tuberculosis programs
Non-rifamycin regimens	Used when resistance, intolerance or drug interactions prevent rifampin use

Rifapentine has greater differentiation in certain shorter-course prevention regimens. Rifabutin can be selected when rifampin’s potent enzyme induction creates clinically significant interactions, particularly with some antiretroviral therapies.

What formulation patents protect Rifadin?

The original oral capsule formulation has no commercially significant remaining exclusivity. Rifampin formulation development remains technically relevant because the drug has demanding physical and chemical properties, including polymorphism, limited aqueous solubility and sensitivity to formulation conditions.

Potentially protectable formulation areas include:

• Improved dissolution
• Reduced food-effect variability
• Modified release
• Pediatric dispersible products
• Combination tablets
• Long-acting delivery systems
• Nanoparticle formulations
• Stability improvements
• Reduced interaction potential

These technologies may support a separate patent position, but they do not create current exclusivity for traditional Rifadin capsules.

What method-of-use patents affect Rifadin?

Method-of-use patents covering the historical use of rifampin in tuberculosis and prophylaxis have expired. Newer method patents may cover:

• Shorter tuberculosis prevention regimens
• Rifampin use with newer antituberculosis agents
• Treatment of drug-resistant tuberculosis
• Specific dosing schedules
• Host-directed or immune-modulating combinations

The commercial value of such patents depends on guideline adoption and reimbursement. A method patent has limited practical impact if physicians and public-health programs can use an unpatented alternative regimen.

What is the Paragraph IV risk for Rifadin?

Paragraph IV risk is low for the original Rifadin product because the principal patents have expired. A Paragraph IV certification is relevant when an ANDA applicant challenges an unexpired listed patent. With no material current patent barrier for the mature rifampin capsule product, generic entry is more likely to proceed through ordinary ANDA certification rather than a high-value patent challenge.

No major, continuing Paragraph IV litigation appears to define the commercial outlook for Rifadin. Any dispute involving a newer rifampin formulation or combination product would need to be analyzed separately from the legacy brand.

What patent litigation affects Rifadin?

Rifadin is not associated with an active patent litigation profile comparable to high-value branded products in oncology, immunology or rare diseases. The absence of a current blocking patent estate reduces the probability of a litigation-driven launch delay.

The main legal risks are commercial rather than patent-centric:

• Product liability claims
• Manufacturing violations
• Good manufacturing practice enforcement
• Supply-contract disputes
• Procurement challenges
• Regulatory action involving quality or bioequivalence
• Trademark or brand confusion involving rifampin products

Has Sanofi licensed Rifadin or rifampin rights?

No major recent licensing transaction appears to drive the current Rifadin commercial position. The product is a mature Sanofi-associated brand rather than a newly licensed growth asset. Any regional distribution, supply or commercialization agreements would not materially change the underlying patent position.

The more important commercial structure is procurement contracting. Government tenders and international tuberculosis programs can shift market share between manufacturers without changing the clinical demand for rifampin.

How strong is the Rifadin patent estate?

The patent estate is weak for the original product and stronger only in narrow technical areas.

Patent-strength factor	Assessment
Core molecule	None of practical commercial duration
Traditional capsule	Low
Basic tuberculosis use	Expired
New formulation technology	Potentially moderate, depending on claims
Manufacturing know-how	Potential barrier but not equivalent to patent exclusivity
Regulatory exclusivity	None of material commercial duration
Litigation leverage	Low
Generic entry resistance	Low

Manufacturing know-how can still create operational advantages. Rifampin production requires control of solid-state properties, impurity profiles, stability and batch consistency. Those factors may raise the cost of entry, but they do not prevent competition when alternative manufacturers can demonstrate equivalence and meet regulatory standards.

What is Rifadin’s market size and financial trajectory?

Rifadin-specific revenue is not separately disclosed in Sanofi’s public financial reporting. The brand is therefore not suitable for a precise standalone revenue forecast based on company filings.

The financial trajectory is nevertheless clear:

1. Revenue peaked during the protected-brand period.
2. Generic competition compressed pricing after exclusivity loss.
3. Unit demand remained tied to tuberculosis incidence and public-health procurement.
4. Brand revenue became less material relative to Sanofi’s major specialty-care and vaccine franchises.
5. Current economics depend more on supply contracts and residual brand demand than on premium pricing.

Global tuberculosis incidence remains large. WHO estimated approximately 10.8 million people developed tuberculosis in 2023, with more than 1 million deaths (WHO, 2024). That epidemiology supports durable ingredient demand, but much of the value accrues to generic manufacturers and public-health suppliers rather than the original brand.

The commercial distinction is important:

Metric	Rifadin implication
Patient need	High and persistent
Brand pricing power	Low
Generic substitution	High
Public procurement exposure	High
Revenue volatility	Driven by tenders and supply
Growth profile	Mature to declining for the brand
Ingredient demand	Stable to moderately growing with TB programs
Margin profile	Lower than protected branded medicines

Rifadin may retain value where prescribers, hospitals or distributors prefer the branded product, but that value is constrained by therapeutic substitutability and generic availability.

What generic launch scenarios exist for Rifadin?

Base case: continued generic substitution

Generic rifampin remains the dominant commercial pathway. The brand retains limited residual demand, while public-health programs purchase lower-cost generic or fixed-dose products.

Supply disruption scenario

Shortages, manufacturing interruptions or quality failures can temporarily increase demand for available branded inventory. This can support short-term price increases, but it does not create durable exclusivity.

Formulation differentiation scenario

A manufacturer with an improved pediatric, dispersible, modified-release or combination formulation could obtain commercial differentiation. The value would depend on regulatory approval, guideline adoption and tender eligibility.

Competitive regimen scenario

Greater adoption of rifapentine-based prevention regimens or other shorter-course tuberculosis programs could reduce demand for some rifampin uses while preserving or increasing demand in other treatment settings.

What is the biosimilar risk for Rifadin?

Biosimilar risk does not apply. Rifampin is a small-molecule chemical drug, not a biologic. The relevant competitive threat is generic substitution through the ANDA pathway.

Generic risk is high because:

• The molecule is well characterized.
• The core patents are expired.
• The product has established clinical use.
• Multiple manufacturers can potentially supply it.
• Public-health buyers prioritize cost and availability.
• Physicians can substitute therapeutically equivalent products.

What is the geographic coverage of Rifadin?

Rifampin is marketed or supplied globally, but the Rifadin brand has different commercial status by jurisdiction. In many countries, rifampicin is purchased under generic names or as part of fixed-dose combinations. Brand strength is generally greater in markets where Sanofi maintains active distribution and weaker in tender-driven low- and middle-income markets.

Geographic commercial exposure is concentrated in:

• Countries with substantial tuberculosis burden
• National tuberculosis programs
• Hospital and infectious-disease channels
• International procurement organizations
• Markets requiring quality-assured imported products

Local regulatory approvals, World Health Organization prequalification and national tender participation are more important than worldwide brand recognition.

Key Takeaways

• Rifadin is the legacy branded form of rifampin, a core tuberculosis antibiotic.
• Its original patent and regulatory exclusivity have expired.
• No material current Orange Book barrier appears to prevent generic competition for the traditional capsule product.
• Paragraph IV litigation and active patent disputes are not central to the brand’s current outlook.
• Formulation, manufacturing and combination-product patents may exist in narrow areas but do not protect ordinary Rifadin capsules.
• Sanofi does not separately disclose Rifadin revenue, preventing a reliable brand-level financial estimate.
• The brand’s financial trajectory is mature to declining, while rifampin ingredient demand remains supported by global tuberculosis programs.
• Generic substitution, government tenders and supply reliability determine market share.
• Biosimilar risk is irrelevant; generic risk is high.
• The main commercial opportunity lies in quality-assured supply, fixed-dose combinations and differentiated delivery systems rather than legacy brand pricing.

FAQs About Rifadin Patent and Market Exposure

Is Rifadin still under patent protection?

No material composition or traditional capsule patent protection remains for Rifadin. Any surviving rights would likely concern narrow formulations, combinations or manufacturing processes.

Can a generic manufacturer launch rifampin without a Paragraph IV challenge?

Yes. Because the principal legacy protections have expired, an ANDA applicant may generally proceed without relying on a high-value Paragraph IV patent challenge to enter the traditional rifampin capsule market.

Is Rifadin more valuable than generic rifampin?

The branded product may retain distribution or prescribing value in selected markets, but generic rifampin has the stronger long-term commercial position in price-sensitive tuberculosis procurement.

Could rifapentine replace Rifadin?

Rifapentine can replace rifampin in selected tuberculosis prevention and treatment regimens, but it is not a universal substitute. Clinical indication, regimen duration, drug interactions, cost and local guidelines determine product selection.

Does Rifadin have biosimilar competition?

No. Rifadin is a small-molecule drug. Its competitors are generic rifampin products, not biosimilars.

References

1. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

2. Food and Drug Administration. (n.d.). Rifadin prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/

3. Sanofi. (2024). Annual report 2023. https://www.sanofi.com/

4. World Health Organization. (2023). WHO consolidated guidelines on tuberculosis: Module 4: Treatment - drug-susceptible tuberculosis treatment. https://www.who.int/

5. World Health Organization. (2024). Global tuberculosis report 2024. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024